Meeting
2015 ASCO Annual Meeting
A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors.
Authors
Drew Warren Rasco
START Center for Cancer Care, San Antonio, TX
Drew Warren Rasco , Amita Patnaik , Anthony W. Tolcher , Kyriakos P. Papadopoulos , Christine Peterson , Ely Benaim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Cytotoxic and Other Novel Agents
Clinical Trial Registration Number
NCT02030067
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS2605)
DOI
10.1200/jco.2015.33.15_suppl.tps2605
Abstract #
TPS2605
Poster Bd #
319a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
First Author: Thorsten Oliver Goetze
Poster
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors.
First Author: Junli Xue